X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (48337) 48337
Book Review (7365) 7365
Publication (3363) 3363
Newsletter (467) 467
Book Chapter (91) 91
Conference Proceeding (63) 63
Book / eBook (59) 59
Dissertation (55) 55
Newspaper Article (29) 29
Magazine Article (14) 14
Data Set (6) 6
Paper (3) 3
Web Resource (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (41443) 41443
humans (39945) 39945
oncology (24809) 24809
female (20125) 20125
cancer (18117) 18117
male (17440) 17440
middle aged (15222) 15222
aged (13082) 13082
lung neoplasms - genetics (12819) 12819
lung cancer (11620) 11620
carcinoma, non-small-cell lung - genetics (11377) 11377
prognosis (10889) 10889
lung neoplasms - pathology (10692) 10692
cell line, tumor (10305) 10305
expression (10200) 10200
adult (9773) 9773
tumors (9676) 9676
metastasis (9505) 9505
carcinoma (9237) 9237
animals (8779) 8779
genetic aspects (8686) 8686
carcinoma, non-small-cell lung - pathology (8661) 8661
gene expression (8390) 8390
apoptosis (7975) 7975
research (7850) 7850
chemotherapy (7422) 7422
mutation (7249) 7249
gene expression regulation, neoplastic (6974) 6974
analysis (6834) 6834
lung cancer, non-small cell (6691) 6691
lung neoplasms - drug therapy (6550) 6550
carcinoma, non-small-cell lung - drug therapy (6436) 6436
proteins (6413) 6413
care and treatment (6320) 6320
immunohistochemistry (5970) 5970
health aspects (5897) 5897
aged, 80 and over (5819) 5819
cell biology (5817) 5817
lung neoplasms - metabolism (5782) 5782
development and progression (5667) 5667
survival (5624) 5624
mice (5605) 5605
medical prognosis (4968) 4968
breast-cancer (4964) 4964
neoplasm staging (4926) 4926
carcinoma, non-small-cell lung - metabolism (4747) 4747
adenocarcinoma (4614) 4614
research article (4564) 4564
pathology (4531) 4531
cell proliferation (4510) 4510
cancer therapies (4444) 4444
kinases (4436) 4436
lung-cancer (4237) 4237
medicine (4210) 4210
biochemistry & molecular biology (4185) 4185
signal transduction (3964) 3964
genes (3961) 3961
non-small cell lung cancer (3958) 3958
studies (3772) 3772
multidisciplinary sciences (3764) 3764
squamous cell carcinoma (3721) 3721
patients (3529) 3529
biomarkers (3523) 3523
receptor, epidermal growth factor - genetics (3519) 3519
biomarkers, tumor - genetics (3407) 3407
antineoplastic agents - therapeutic use (3393) 3393
breast cancer (3361) 3361
growth (3355) 3355
proliferation (3292) 3292
cell cycle (3289) 3289
cancer research (3280) 3280
respiratory system (3192) 3192
medicine, research & experimental (3148) 3148
carcinoma, squamous cell - genetics (3117) 3117
science (3078) 3078
cell growth (3024) 3024
micrornas - genetics (2997) 2997
treatment outcome (2979) 2979
antineoplastic agents - pharmacology (2952) 2952
risk factors (2948) 2948
article (2939) 2939
lung neoplasms - mortality (2916) 2916
metastases (2906) 2906
adenocarcinoma - genetics (2901) 2901
gefitinib (2877) 2877
polymerase chain reaction (2853) 2853
gene (2842) 2842
survival analysis (2841) 2841
hepatocellular-carcinoma (2840) 2840
surgery (2837) 2837
diagnosis (2828) 2828
cell lung-cancer (2822) 2822
down-regulation (2794) 2794
microrna (2720) 2720
carcinoma, squamous cell - pathology (2689) 2689
squamous-cell carcinoma (2680) 2680
medicine & public health (2676) 2676
medical research (2653) 2653
activation (2630) 2630
invasion (2607) 2607
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (34) 34
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (16) 16
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Online Resources - Online (4) 4
St. Michael's Hospital - Stacks (4) 4
Gerstein Science - Circulation Desk (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Humber River Regional Hospital - Finch Stacks (2) 2
Markham Stouffville Hospital - Stacks (2) 2
St Josephs Health Centre - Stacks (2) 2
Sunnybrook Health Sciences Centre - Online (2) 2
Credit Valley Hospital - Special Collections (1) 1
Gerstein Science - Reference (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Markham Stouffville Hospital - Storage (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
Toronto East General Hospital - Online (1) 1
Trillium Health Centre - Stacks (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (48001) 48001
Chinese (571) 571
French (105) 105
Japanese (83) 83
German (73) 73
Russian (46) 46
Spanish (20) 20
Polish (19) 19
Portuguese (13) 13
Korean (12) 12
Hungarian (7) 7
Czech (6) 6
Italian (5) 5
Croatian (2) 2
Dutch (2) 2
Slovak (2) 2
Turkish (2) 2
Arabic (1) 1
Danish (1) 1
Norwegian (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 21, pp. 1963 - 1971
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article
by Jamal-Hanjani, Mariam and Wilson, Gareth A and McGranahan, Nicholas and Birkbak, Nicolai J and Watkins, Thomas B.K and Veeriah, Selvaraju and Shafi, Seema and Johnson, Diana H and Mitter, Richard and Rosenthal, Rachel and Salm, Max and Horswell, Stuart and Escudero, Mickael and Matthews, Nik and Rowan, Andrew and Chambers, Tim and Moore, David A and Turajlic, Samra and Xu, Hang and Lee, Siow-Ming and Forster, Martin D and Ahmad, Tanya and Hiley, Crispin T and Abbosh, Christopher and Falzon, Mary and Borg, Elaine and Marafioti, Teresa and Lawrence, David and Hayward, Martin and Kolvekar, Shyam and Panagiotopoulos, Nikolaos and Janes, Sam M and Thakrar, Ricky and Ahmed, Asia and Blackhall, Fiona and Summers, Yvonne and Shah, Rajesh and Joseph, Leena and Quinn, Anne M and Crosbie, Phil A and Naidu, Babu and Middleton, Gary and Langman, Gerald and Trotter, Simon and Nicolson, Marianne and Remmen, Hardy and Kerr, Keith and Chetty, Mahendran and Gomersall, Lesley and Fennell, Dean A and Nakas, Apostolos and Rathinam, Sridhar and Anand, Girija and Khan, Sajid and Russell, Peter and Ezhil, Veni and Ismail, Babikir and Irvin-Sellers, Melanie and Prakash, Vineet and Lester, Jason F and Kornaszewska, Malgorzata and Attanoos, Richard and Adams, Haydn and Davies, Helen and Dentro, Stefan and Taniere, Philippe and O’Sullivan, Brendan and Lowe, Helen L and Hartley, John A and Iles, Natasha and Bell, Harriet and Ngai, Yenting and Shaw, Jacqui A and Herrero, Javier and Szallasi, Zoltan and Schwarz, Roland F and Stewart, Aengus and Quezada, Sergio A and Le Quesne, John and Van Loo, Peter and Dive, Caroline and Hackshaw, Allan and Swanton, Charles and TRACERx Consortium
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2109 - 2121
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in... 
TRIALS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | MUTATION | ACQUIRED-RESISTANCE | CRIZOTINIB | CLINICAL RESISTANCE | KINASE INHIBITOR | STI-571 | EGFR | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
by Ettinger, David S and Ettinger, David S and Wood, Douglas E and Wood, Douglas E and Akerley, Wallace and Akerley, Wallace and Bazhenova, Lyudmila A and Bazhenova, Lyudmila A and Borghaei, Hossein and Borghaei, Hossein and Camidge, David R.oss and Camidge, David Ross and Cheney, Richard T and Cheney, Richard T and Chirieac, Lucian R and Chirieac, Lucian R and D'Amico, Thomas A and D'Amico, Thomas A and Demmy, Todd L and Demmy, Todd L and Dilling, Thomas J and Dilling, Thomas J and Dobelbower, M. Chris and Dobelbower, M Chris and Govindan, Ramaswamy and Govindan, Ramaswamy and Grannis, Frederic W and Grannis, Frederic W and Horn, Leora and Horn, Leora and Jahan, Thierry M and Jahan, Thierry M and Komaki, Ritsuko and Komaki, Ritsuko and Krug, Lee M and Krug, Lee M and Lackner, Rudy P and Lackner, Rudy P and Lanuti, Michael and Lanuti, Michael and Lilenbaum, Rogerio and Lilenbaum, Rogerio and Lin, Jules and Lin, Jules and Loo, Billy W and Loo, Billy W and Martins, Renato and Martins, Renato and Otterson, Gregory A and Otterson, Gregory A and Patel, Jyoti D and Patel, Jyoti D and Pisters, Katherine M and Pisters, Katherine M and Reckamp, Karen and Reckamp, Karen and Riely, Gregory J and Riely, Gregory J and Rohren, Eric and Rohren, Eric and Schild, Steven E and Schild, Steven E and Shapiro, Theresa A and Shapiro, Theresa A and Swanson, Scott J and Swanson, Scott J and Tauer, Kurt and Tauer, Kurt and Yang, Stephen C and Yang, Stephen C and Gregory, Kristina and Gregory, Kristina and Hughes, Miranda and Hughes, Miranda and National comprehensive cancer network
Journal of the National Comprehensive Cancer Network : JNCCN, ISSN 1540-1405, 05/2015, Volume 13, Issue 5, pp. 515 - 524
These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very... 
Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - therapy | Genetic Testing | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Carcinoma, Non-Small-Cell Lung - diagnosis | Lung Neoplasms - therapy | Lung Neoplasms - diagnosis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | MUTATIONS | AFATINIB | IRREVERSIBLE EGFR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1700 - 1709
Patients with non–small-cell lung cancer and mutated epidermal growth factor receptors who develop resistance to EGFR inhibitors through a particular mutation... 
TYROSINE KINASE INHIBITORS | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | MUTATIONS | AFATINIB | ERLOTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Hyperglycemia - chemically induced | Antineoplastic Agents - adverse effects | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Hyperglycemia | Chemotherapy | Epidermal growth factor | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Genes | Antitumor activity | Pharmacokinetics | Patients | Index Medicus |